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Effect of fibroblast growth factor-23 on phosphate transport in
proximal tubules.
Background. Fibroblast growth factor-23 (FGF-23) has been
implicated in the renal phosphate wasting in tumor-induced
osteomalacia, X-linked hypophosphatemia, and autosomal-
dominant hypophosphatemic rickets.
Methods. In this in vitro microperfusion study we examined
if FGF23R176Q, a stable mutant of FGF-23, impairs phos-
phate transport in rabbit proximal convoluted and proximal
straight tubules perfused in vitro. We also examined if heparin,
a molecule that is known to facilitate binding of FGFs to their
receptor was necessary for the action of FGF23R176Q on trans-
port.
Results. In the presence of heparin, FGF23R176Q reduced
phosphate transport from 10.8 ± 2.0 to 9.9 ± 1.9 pmol/mm/min
in proximal convoluted tubules and 1.0 ± 0.2 to 0.8 ±
0.2 pmol/mm/min in proximal straight tubules (both P < 0.05).
There was no effect of FGF23R176Q in the absence of heparin.
Incubation of finely minced mouse renal cortical tissue in tissue
culture media for 3 hours resulted in a reduction in brush bor-
der membrane vesicles (BBMV) sodium-dependent phosphate
transport (NaPi-2A) protein abundance in the presence but not
in the absence of heparin.
Conclusion. These data demonstrate that the inhibition of
phosphate transport by FGF23R176Q in vitro requires heparin.
The action of FGF23R176Q is associated with a reduction in
BBMV NaPi-2A protein abundance.
Fibroblast growth factor-23 (FGF-23) was first cloned
from the tumor of a patient with tumor-induced osteo-
malacia; a rare paraneoplastic disorder that can be seen
in patients with mesenchymal tumors [1]. These tumors
cause renal phosphate wasting by secreting FGF-23 [2–5]
and likely other phosphaturic peptides previously known
as phosphatonins [2]. Tumor resection results in a reduc-
tion in FGF-23 to normal levels with a concomitant rise
in serum phosphate levels [6].
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Tumor-induced osteomalacia is related to two other hy-
perphosphaturic disorders, X-linked hypophosphatemia
and autosomal-dominant hypophosphatemic rickets.
X-linked hypophosphatemia is due to a mutation in the
PHEX gene [7–10]. The PHEX gene is a phosphate-
regulating gene with endopeptidase activity, which is
located on the X chromosome. X-linked hypophos-
phatemia may be due to failure to inactivate normal cir-
culating FGF-23 [11]. However, others have found that
FGF-23 is not a PHEX substrate [12, 13], and that in some
way absence of PHEX results in increased production
of FGF-23 [13]. Most patients with X-linked hypophos-
phatemia have inappropriately high levels of FGF-23
[14–16], whereas patients with autosomal-dominant hy-
pophosphatemic rickets have a R176Q mutation in FGF-
23 which resists proteolytic cleavage resulting in in-
creased serum levels [4, 17–20]. FGF-23 is also asso-
ciated with abnormal vitamin D metabolism. Injection
of FGF-23 results in a decrease in serum 1,25 dihy-
droxy vitamin D levels [21]. FGF-23 causes both a re-
duction in 25-hydroxyvitamin D-1a-hydroxylase mRNA
abundance and an increase in 25-hydroxyvitamin D-24-
hydroxylase mRNA abundance [21]. These three disor-
ders are thus characterized by hypophosphatemia, hyper-
phosphaturia, inappropriately normal 1,25(OH)2 vitamin
D levels for the degree of hypophosphatemia and defec-
tive bone mineralization.
While FGF-23 has been associated with disorders
with impaired renal phosphate absorption, it is unclear
how FGF-23 affects phosphate transport [1, 17, 22].
The purpose of the present study was to determine if
FGF23R176Q has a direct epithelial action to inhibit
phosphate transport in the proximal straight and prox-
imal convoluted tubules.
METHODS
In vitro microperfusion flux studies
Isolated segments of proximal convoluted tubules and
straight tubules were perfused as previously described
from New Zealand White rabbits [23, 24]. Briefly, tubules
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were dissected in Hanks’ balanced salt solution (HBSS)
containing (in mmol/L) 137 NaCl, 5 KCl, 0.8 MgSO4,
0.33 Na2HPO4, 0.44 KH2PO4, 1 MgCl2 10 Tris (hydrox-
ymethyl) aminomethane hydrochloride, 0.25 CaCl2, 2
glutamine, and 2 L-lactate at 4◦C. Dissected tubules were
then transferred to a 1.2 mL temperature-controlled bath
chamber and perfused using concentric glass pipettes at
38◦C.
Proximal tubules (straight) were perfused at
∼10 nL/min. The perfusion solution was an ultrafiltrate-
like solution containing (in mmol/L) 115 NaCl, 25
NaHCO3, 4.0 Na2HPO4, 10 sodium acetate, 1.8 CaCl2,
1 MgSO4, 5 KCl, 8.3 glucose, and 5 alanine. The bathing
solution contained 6 g/dL bovine serum albumin (BSA).
The osmolality of all solutions was adjusted to 295
mmol/kg H2O. The pH and osmolality of the bathing
solution were maintained constant by continuously
changing the bath at a rate of at least 0.5 mL/min.
Net volume absorption (JV, in nL/mm−1/min−1) was
measured as the difference between the perfusion (VO)
and collection (VL) rates (nL/min) normalized per
millimeter of tubular length (L). Dialyzed [methoxy-3H]
inulin was added to the perfusate at a concentration
of 75 lCi/mL so that the perfusion rate could be
calculated. The collection rate was measured with a
50 nL constant-volume pipette. The length (in mm) was
measured with an eyepiece micrometer. Tubules were
incubated for 15 to 20 minutes before initiation of the
control period. Phosphate and glucose transport were
determined with 32P and 14C, respectively (50 lCi/mL),
using the following equation:
JPO4 or JGlu = [(VoC∗o − VLC∗L)/L]Po/C∗o
where PO is the phosphate (or glucose) concentration in
the perfusate and C∗O and C
∗
L were the phosphate (or glu-
cose) concentrations in the perfusate and collected fluids,
respectively, in counts per minute per nanoliter.
Proximal tubules were perfused for at least 20 minutes
prior to the initiation of the control period. After at least
four collections, the bathing solution was changed to one
that contained either 20 ng/mL FGF-23 or FGF23R176Q
(in the presence or absence of 10 lg/mL heparin), a sta-
ble mutant of FGF-23. FGF-23 was not available for all
experimental protocols as it was no longer being pro-
duced and therefore FGF23R176Q a stable mutant was
utilized where designated. FGF23R176Q disrupts a con-
sensus proteolytic cleavage motif but has the same action
as FGF-23 [20, 25].
Tubule preparation and brush border membrane
vesicle isolation
C57/B6 mouse kidneys were used to determine if
FGF23R176Q caused a reduction in sodium-dependent
phosphate transport (NaPi-2A) brush border membrane
abundance since our antibody, a generous gift from Dr.
Ju¨rg Biber (University of Zu¨rich, Switzerland), recog-
nized mouse NaPi-2A. C57/B6 mouse kidneys were re-
moved and the cortex minced fine with a razor blade.
The cortical tissue was placed in Dulbecco’s modified
Eagle’s media (DMEM) containing 2 mmol/L lactate and
2 mmol/L butyrate and incubated in a 5% CO2 incuba-
tor with 20 ng/mL FGF23R176Q. The cortical tissue was
continuously gently shaken for 3 hours. The tissue was
then placed in isolation buffer containing 300 mmol/L
mannitol, 16 mmol/L N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic acid (Hepes), 5 mmol/L ethylene glycol-
bis (b -aminoethyl ether) N,N,N′N′-tetraacetic acid
(EGTA) titrated to pH 7.4 with Tris. The isolation buffer
contained aprotinin (2 lg/mL), leupeptin (2 lg/mL),
and phenyl-methylsulfonyl fluoride (PMSF) (100 lg/mL).
The cortical tissue was homogenized with 20 strokes of
a Potter Elvehjem homogenizer at 4◦C. Brush border
membrane vesicles (BBMV) were then isolated by dif-
ferential centrifugation and magnesium precipitation as
described previously [26]. The final BBMV fraction was
resuspended in isolation buffer. Protein was assayed us-
ing the Lowry method with crystalline BSA as the stan-
dard [27].
Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and immunoblotting
Brush border membrane proteins (25 lg/lane) were
denatured and then separated on a 7.5% polyacrylamide
gel using SDS-PAGE as previously described [28, 29].
The proteins were transferred overnight to a polyvinyli-
dene diflouride (PVDF) membrane at 120 to 140 mA at
4◦C. The blot was blocked with fresh Blotto [5% non-
fat milk and 0.1% Tween 20 in phosphate-buffered saline
(PBS), pH 7.4] for 1 hour followed by incubation with
primary antibody to NaPi-2A. NaPi-2A antibody was
added at 1:1000 dilution overnight at 4◦C. The blot was
then washed extensively with Blotto. The secondary an-
tibody, horseradish peroxidase–conjugated donkey an-
tirabbit immunoglobulin was added at 1:10,000 dilution
and incubated in room temperature for 1 hour. The blot
was again washed with Blotto, and enhanced chemilumi-
nescence was used to detect bound antibody (Amersham
Life Science, Arlington Heights, IL, USA). The NaPi-2A
protein abundance was quantitated using densitometry.
Equal loading of the samples was confirmed using an anti-
body to b-actin at a 1:5000 dilution (Sigma Biochemicals
and Reagents, St. Louis, MO, USA).
Data are expressed as mean ± SE. The Student t test
for paired and unpaired data were used to determine sta-
tistical significance.
RESULTS
In the first series of experiments, we examined if
20 ng/mL FGF-23 directly affected volume absorp-
tion and phosphate transport in the rabbit proximal
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Table 1. Effect of fibroblast growth factor-23 (FGF-23) (JPhos) on phosphate transport and volume absorption (Jv) in the proximal convoluted
tubule (PTC)
Vo control Vo FGF-23 Jv control Jv FGF-23 JPhos control JPhos FGF-23
Experimental protocol Number L mm nL/min nL/min nL/mm/min nL/mm/min pmol/mm/min pmol/mm/min
PCT bath FGF23R176Q
20 ng/mL
7 1.5 ± 0.2 10.39 ± 0.29 10.77 ± 0.30 0.74 ± 0.07 0.74 ± 0.06 15.3 ± 1.1 14.6 ± 1.3
PCT bath FGF-23 20 ng/mL 5 1.5 ± 0.2 11.34 ± 0.72 10.77 ± 0.31 0.97 ± 0.24 0.98 ± 0.20 13.5 ± 3.2 13.8 ± 2.7
PCT bath FGF23R176Q
20 ng/mL plus 10 lg/mL
heparin
6 1.5 ± 0.2 11.01 ± 0.53 10.82 ± 0.37 0.74 ± 0.15 0.59 ± 0.11a 10.8 ± 2.0 9.9 ± 1.9a
aP < 0.05 vs. control.
Table 2. Effect of fibroblast growth factor-23 (FGF-23) (JPhos) on phosphate transport and volume absorption (Jv) in the proximal straight
tubule (PST)
Vo control Vo FGF-23 Jv control Jv FGF-23 JPhos control JPhos FGF-23
Experimental protocol Number L mm nL/min nL/min nL/mm/min nL/mm/min pmol/mm/min pmol/mm/min
PST bath FGF23R176Q
20 ng/mL
5 1.7 ± 0.1 9.32 ± 0.40 9.47 ± 0.33 0.30 ± 0.04 0.38 ± 0.04 1.3 ± 0.2 1.5 ± 0.3
PST bath FGF-23 20 ng/mL 8 1.8 ± 0.2 9.91 ± 0.36 9.54 ± 0.41 0.48 ± 0.07 0.44 ± 0.10 2.3 ± 0.9 2.3 ± 1.0
PST bath FGF23R176Q
20 ng/mL plus 10 lg/mL
Heparin
5 1.8 ± 0.2 10.34 ± 0.27 9.78 ± 0.24 0.38 ± 0.10 0.35 ± 0.10 1.0 ± 0.2 0.8 ± 0.2a
aP < 0.05 vs. control.
convoluted or proximal straight tubules. This dose of
FGF-23 was chosen since it was shown to produce maxi-
mal inhibition of phosphate transport in opossum kidney
cells and it is comparable to the level measured in pa-
tients with renal failure [22, 30]. As shown in Tables 1
and 2, there was no effect of FGF-23 or FGF23R176Q
on either phosphate transport or volume absorption in
either proximal straight or proximal convoluted tubules.
We next examined whether FGF23R176Q inhibited
phosphate transport or volume absorption in proximal
convoluted and proximal straight tubules in the presence
of 10 lg/mL heparin. Heparin has been show to facili-
tate binding of FGF-23 to its receptor [31, 32]. In these
experiments heparin was present in the control period
as well as the experimental period when FGF23R176Q
was added. As is seen in Tables 1 and 2 and Figures 1
and 2, FGF23R176Q inhibited phosphate transport in the
presence of heparin. Interestingly, FGF23R176Q inhib-
ited volume absorption in proximal convoluted tubules
but not in proximal straight tubules. In a separate group
of tubules we examined if 20 ng/mL FGF23R176Q caused
a generalized decrease in solute transport by examining
its effect on glucose transport in proximal convoluted
tubules with and without heparin in the bathing solution.
In tubules perfused without heparin in the bathing so-
lution, Jglu was 47.5 ± 7.5 pmol/mm/min in the control
period and 47.9 ± 6.4 pmol/mm/min with FGF23R176Q
in the bathing solution (P = NS). In tubules with heparin
in the bathing solution, there was no effect of 20 ng/mL
FGF23R176Q on glucose transport. The rates of glucose
transport were 48.0 ± 1.8 pmol/mm/min in the control
period and 46.4 ± 1.4 pmol/mm/min upon addition of
FGF23R176Q to the bathing solution (P = NS). Thus
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Fig. 1. Effect of FGF23R176Q on phosphate transport in proximal
convoluted tubules perfused in vitro. There was 10 lg/mL of heparin
in the bathing solution in both the control period and the experimental
period when FGF23R176Q was added to the bathing solution. There
was a significant inhibition in phosphate transport with addition of
FGF23R176Q.
FGF23R176Q does not cause a nonspecific decrease in
solute transport.
In the final series of experiments, we examined whether
incubation of proximal tubules with FGF23R176Q
resulted in a reduction in brush border membrane
NaPi-2 expression. As seen in Figure 3, proximal tubules
incubated with FGF23R176Q without heparin had no re-
duction in brush border membrane vesicle NaPi-2A ex-
pression (N = 8) (NaPi-2A/b-actin ratio of 0.80 ± 0.05
vs. 0.79±0.05) (P = NS) but proximal tubules incubated
with FGF23R176Q and 10 lg/mL heparin had a signif-
icant decrease in BBMV NaPi-2A expression (N = 12)
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Fig. 2. Effect of FGF23R176Q on phosphate transport in proximal
straight tubules perfused in vitro. There was 10 lg/mL of heparin in
the bathing solution in both the control period and the experimental
period when FGF23R176Q was added to the bathing solution. There
was a significant inhibition in phosphate transport with addition of
FGF23R176Q.
Heparin
No heparin
NaPi-2
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Cont FGF23
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Fig. 3. Effect of FGF23R176Q in the presence or absence of hep-
arin on NaPi-2A protein abundance in mouse brush border membrane
vesicles. Brush border membrane vesicles were prepared from finely
minced cortical tissue incubated in vitro in Dulbecco’s modified Ea-
gle’s media containing 2 mmol/L lactate and 2 mmol/L butyrate for 3
hours at 37◦. There was a reduction in NaPi-2A protein abundance in
brush border membranes prepared from tubules incubated with heparin
and FGF23R176Q but not from FGF23R176Q alone. Heparin was also
present in the control tubules examining the effect of FGF23R176Q in
the presence of heparin.
(NaPi-2A/b-actin ratio of 0.67 ± 0.07 vs. 0.43 ± 0.08) (P <
0.05).
DISCUSSION
In this study we examined the effect of 20 ng/mL FGF-
23 and FGF23R176Q on phosphate transport and volume
absorption in proximal convoluted and straight tubules in
vitro. This dose was shown to produce maximal inhibition
of phosphate transport when added to opossum kidney
cells in vitro [22]. This level of FGF-23 also has physio-
logic relevance since normal values range between 10 and
50ng/L [6] and are increased 100- to 1000-fold in patients
with end-stage renal disease (ESRD) [30].
There is evidence from the crystal structure of FGF
receptor that heparin is necessary for the complete as-
sembly of FGF and the FGF receptor [31, 32]. While
one group has found that FGF-23 inhibits phosphate
transport in opossum kidney cells [17], a cell line with
characteristics of proximal tubule cells, others have not
seen an effect of FGF-23 in the absence of 10 lg/mL
heparin [1, 22]. Indeed Bowe et al [17] have found that
the inhibitory effect of FGF-23 in opossum kidney cells
was abrogated in the presence of heparin [17]. Our data
suggest that in both proximal tubules perfused in vitro
and in proximal tubules incubated with FGF23R176Q,
there is a requirement for heparin for the inhibitory
effect of FGF23R176Q on phosphate transport. While
FGF23R176Q disrupts a consensus proteolytic cleavage
motif but has the same action as FGF-23 [20, 25], a short-
coming of this study is that FGF-23 was not examined
in the presence of heparin. The discrepancy between our
data and studies that show that heparin blocks the effect
of FGF-23 is unclear.
Parathyroid hormone (PTH) is a major modulator of
phosphate transport. Of interest, the effects of PTH and
FGF-23 on proximal tubule phosphate and volume ab-
sorption in the rabbit are different. PTH inhibits volume
absorption in the rabbit proximal convoluted tubule, but
has no effect on phosphate transport [33–35]. By con-
trast, FGF23R176Q inhibited both volume absorption
and phosphate transport in proximal convoluted tubules
in the present study. In the proximal straight tubule, PTH
inhibited both phosphate and volume absorption [33–35],
while in the current study, FGF23R176Q inhibited phos-
phate transport but had no effect on volume absorption.
Thus it is likely that the two hormones act via different
signal transduction pathways in the two segments. While
the magnitude of the effect of FGF23R176Q on proximal
tubule phosphate transport may seem small, it should be
pointed out that PTH only inhibits phosphate transport
in the proximal straight tubule and the magnitude of the
effect is the same [34], or only slightly smaller than that
previously reported for PTH in that segment [33, 35].
There is evidence that FGF-23 inhibits phosphate
transport in vivo. Injection of recombinant FGF-23 into
mice resulted in a reduction in serum phosphate lev-
els and an increase in urinary excretion of phosphate
[1]. FGF-23 did not cause an increase in glucose or
amino acid excretion [1]. Our results are consistent
with this observation in that we found no effect of
FGF23R176Q on glucose transport in proximal con-
voluted tubules. In addition, implantation of FGF-23
secreting tumor cells into nude mice resulted in the
development of hypophosphatemia, hyperphosphaturia,
an increase in alkaline phosphatase and a reduction
in 1a-vitamin D hydroxylase [1]. Similar studies have
been performed using mutant FGF-23 proteins found
in patients with autosomal-dominant hypophosphatemic
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rickets [18]. Transgenic mice, which overexpress FGF-23,
are growth retarded, have lower serum phosphate lev-
els, hyperphosphaturia, and a reduction in renal NaPi-2
transporter expression compared to their wild-type litter-
mates [36, 37]. In addition they have bone abnormalities
characteristic of rickets or osteomalacia. A single injec-
tion of FGF-23 can cause a reduction in serum phosphate
in as little as 9 hours with a concomitant reduction in renal
NaPi-2A protein abundance [21].
In contradistinction, targeted ablation of FGF-23 re-
sults in a decrease in urinary phosphate excretion, in-
creased serum phosphate and 1,25-dihydroxyvitamin D
levels [38].
Recent studies have provided substantive evidence
that FGF-23 plays a role in normal phosphate homeosta-
sis. A low phosphate diet is known to stimulate prox-
imal tubule phosphate transport [39]. Plasma FGF-23
levels are almost undetectable in mice eating a low phos-
phate diet and FGF-23 levels are higher in mice treated
with a high phosphate diet compared to mice eating
a normal phosphate diet, suggesting that FGF-23 is a
factor mediating the effect renal phosphate transport
with changes in dietary phosphate and serum phosphate
levels [40]. Similar findings have been reported in rats
with a 5/6 nephrectomy with changes in dietary phos-
phate and serum phosphate levels [41]. Administration
of 1,25-dihydroxyvitamin D3 to rats and rats that had a
thyroparathyroidectomy increase FGF-23 levels [41]. In
addition, vitamin D receptor null mice have lower plasma
levels of FGF-23 compared to wild-type mice [40, 41].
These effects of phosphate and 1,25-dihydroxyvitamin D3
on plasma FGF-23 levels are at least in part mediated by
changes in FGF-23 transcription [40].
Our in vitro data and that using opossum kidney cells in
culture [1, 22] show that there is a requirement for heparin
for the action of FGF23R176Q. However, studies where
FGF-23 is administered in vivo demonstrate an increase
in phosphate excretion without the coadministration of
heparin [1, 21]. This apparent discrepancy suggests that
there must be heparin or heparin-like substances in vivo
which are removed when tubules are incubated in vitro.
CONCLUSION
This study shows that FGF23R176Q has a direct ep-
ithelial effect to inhibit phosphate transport in vitro in
the presence of heparin. The effect of FGF23R176Q
can be demonstrated within minutes of administration
to perfused tubules in vitro. Furthermore, the effect of
FGF23R176Q is accompanied by a reduction of BBMV
NaPi-2A abundance.
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